Neill R Graff-Radford1, Lilah M Besser2, Julia E Crook3, Walter A Kukull2, Dennis W Dickson4. 1. Department of Neurology, Mayo Clinic, Jacksonville, FL, USA. Electronic address: graffradford.neill@mayo.edu. 2. Departments of Epidemiology, School of Public Health, University of Washington, Seattle, WA, USA; National Alzheimer's Coordinating Center, Seattle, WA, USA. 3. Department of Statistics, Mayo Clinic, Jacksonville, FL, USA. 4. Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA.
Abstract
INTRODUCTION: Compared to Caucasians, African Americans (AAs) have higher dementia prevalence, different genetic markers, and higher vascular risk factors. However, pathologic underpinnings are unknown. METHODS: We used neuropathologic and clinical data on 110 AA and 2500 Caucasians who were demented before death. The groups were compared regarding demographics, cognition, apolipoprotein E (APOE) genotype, comorbidities, and clinical and neuropathologic characteristics. RESULTS: AA and Caucasians differed in their demographics, cognition at the last visit before death, APOE genotype, presence of hypertension, primary clinical diagnoses, and AD, cerebrovascular disease (CVD), and other neuropathologies such as Lewy body disease (LBD). DISCUSSION: AD, LBD, and CVD pathology were more common and TDP and frontotemporal lobar degeneration-tau less common in AA than in Caucasians. APOE accounted for most of the AD neuropathologic differences. If replicated, the observed differences in underlying neuropathology by race will be important for public health policy and recruitment for and interpreting of clinical trials.
INTRODUCTION: Compared to Caucasians, African Americans (AAs) have higher dementia prevalence, different genetic markers, and higher vascular risk factors. However, pathologic underpinnings are unknown. METHODS: We used neuropathologic and clinical data on 110 AA and 2500 Caucasians who were demented before death. The groups were compared regarding demographics, cognition, apolipoprotein E (APOE) genotype, comorbidities, and clinical and neuropathologic characteristics. RESULTS:AA and Caucasians differed in their demographics, cognition at the last visit before death, APOE genotype, presence of hypertension, primary clinical diagnoses, and AD, cerebrovascular disease (CVD), and other neuropathologies such as Lewy body disease (LBD). DISCUSSION: AD, LBD, and CVD pathology were more common and TDP and frontotemporal lobar degeneration-tau less common in AA than in Caucasians. APOE accounted for most of the AD neuropathologic differences. If replicated, the observed differences in underlying neuropathology by race will be important for public health policy and recruitment for and interpreting of clinical trials.
Authors: Robert C Green; L Adrienne Cupples; Rodney Go; Kelly S Benke; Timi Edeki; Patrick A Griffith; Mary Williams; Yvonne Hipps; Neill Graff-Radford; David Bachman; Lindsay A Farrer Journal: JAMA Date: 2002-01-16 Impact factor: 56.272
Authors: Rachelle S Doody; Ronald G Thomas; Martin Farlow; Takeshi Iwatsubo; Bruno Vellas; Steven Joffe; Karl Kieburtz; Rema Raman; Xiaoying Sun; Paul S Aisen; Eric Siemers; Hong Liu-Seifert; Richard Mohs Journal: N Engl J Med Date: 2014-01-23 Impact factor: 91.245
Authors: L A Farrer; L A Cupples; J L Haines; B Hyman; W A Kukull; R Mayeux; R H Myers; M A Pericak-Vance; N Risch; C M van Duijn Journal: JAMA Date: 1997 Oct 22-29 Impact factor: 56.272
Authors: Teresa Jenica Filshtein; Brittany N Dugger; Lee-Way Jin; John M Olichney; Sarah T Farias; Luis Carvajal-Carmona; Paul Lott; Dan Mungas; Bruce Reed; Laurel A Beckett; Charles DeCarli Journal: J Alzheimers Dis Date: 2019 Impact factor: 4.472
Authors: Eseosa T Ighodaro; Peter T Nelson; Walter A Kukull; Frederick A Schmitt; Erin L Abner; Allison Caban-Holt; Shoshana H Bardach; Derrick C Hord; Crystal M Glover; Gregory A Jicha; Linda J Van Eldik; Alexander X Byrd; Anita Fernander Journal: J Alzheimers Dis Date: 2017 Impact factor: 4.472
Authors: Lilah M Besser; Walter A Kukull; Merilee A Teylan; Eileen H Bigio; Nigel J Cairns; Julia K Kofler; Thomas J Montine; Julie A Schneider; Peter T Nelson Journal: J Neuropathol Exp Neurol Date: 2018-08-01 Impact factor: 3.685
Authors: Melinda C Power; Elizabeth Mormino; Anja Soldan; Bryan D James; Lei Yu; Nicole M Armstrong; Katherine J Bangen; Lisa Delano-Wood; Melissa Lamar; Yen Ying Lim; Kelly Nudelman; Laura Zahodne; Alden L Gross; Dan Mungas; Keith F Widaman; Julie Schneider Journal: Ann Neurol Date: 2018-06-26 Impact factor: 10.422
Authors: Carey E Gleason; Derek Norton; Megan Zuelsdorff; Susan F Benton; Mary F Wyman; Naomi Nystrom; Nickolas Lambrou; Hector Salazar; Rebecca L Koscik; Erin Jonaitis; Fabu Carter; Brieanna Harris; Alexander Gee; Nathaniel Chin; Frederick Ketchum; Sterling C Johnson; Dorothy F Edwards; Cynthia M Carlsson; Walter Kukull; Sanjay Asthana Journal: Alzheimers Dement Date: 2019-10-07 Impact factor: 21.566
Authors: John C Morris; Suzanne E Schindler; Lena M McCue; Krista L Moulder; Tammie L S Benzinger; Carlos Cruchaga; Anne M Fagan; Elizabeth Grant; Brian A Gordon; David M Holtzman; Chengjie Xiong Journal: JAMA Neurol Date: 2019-03-01 Impact factor: 18.302